Altimmune, Inc. (ALT)
2.72
+0.05
(+1.87%)
USD |
NASDAQ |
Oct 07, 12:33
Altimmune Enterprise Value : 228.94M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 228.94M |
| October 05, 2026 | 228.94M |
| October 02, 2026 | 241.58M |
| October 01, 2026 | 246.45M |
| September 30, 2026 | 265.89M |
| September 29, 2026 | 287.29M |
| September 28, 2026 | 285.34M |
| September 25, 2026 | 304.79M |
| September 24, 2026 | 300.90M |
| September 23, 2026 | 330.07M |
| September 22, 2026 | 372.85M |
| September 21, 2026 | 345.63M |
| September 18, 2026 | 341.74M |
| September 17, 2026 | 339.79M |
| September 16, 2026 | 339.79M |
| September 15, 2026 | 337.85M |
| September 14, 2026 | 351.46M |
| September 11, 2026 | 345.63M |
| September 10, 2026 | 349.52M |
| September 09, 2026 | 361.19M |
| September 08, 2026 | 363.13M |
| September 04, 2026 | 374.80M |
| September 03, 2026 | 337.85M |
| September 02, 2026 | 347.57M |
| September 01, 2026 | 310.62M |
| Date | Value |
|---|---|
| August 31, 2026 | 314.51M |
| August 28, 2026 | 314.51M |
| August 27, 2026 | 339.79M |
| August 26, 2026 | 322.29M |
| August 25, 2026 | 332.01M |
| August 24, 2026 | 314.51M |
| August 21, 2026 | 314.51M |
| August 20, 2026 | 283.40M |
| August 19, 2026 | 316.46M |
| August 18, 2026 | 287.29M |
| August 17, 2026 | 293.12M |
| August 14, 2026 | 281.45M |
| August 13, 2026 | 269.78M |
| August 12, 2026 | 279.51M |
| August 11, 2026 | 293.12M |
| August 10, 2026 | 302.84M |
| August 07, 2026 | 308.68M |
| August 06, 2026 | 295.06M |
| August 05, 2026 | 298.95M |
| August 04, 2026 | 306.73M |
| August 03, 2026 | 293.12M |
| July 31, 2026 | 262.00M |
| July 30, 2026 | 289.23M |
| July 29, 2026 | 277.56M |
| July 28, 2026 | 291.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Protalix Biotherapeutics, Inc. | 187.79M |
| Taysha Gene Therapies, Inc. | 1.030B |
| Humacyte, Inc. | 118.92M |
| Liquidia Corp. | 2.207B |
| Agenus, Inc. | 583.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.82M |
| Total Expenses (Quarterly) | 22.82M |
| EPS Diluted (Quarterly) | -0.1231 |
| Earnings Yield | -29.00% |
| Normalized Earnings Yield | -28.89 |